Recommendations Summary
CF: Nutrition Assessment and Diagnosis of Nutrition Status 2020
Click here to see the explanation of recommendation ratings (Strong, Fair, Weak, Consensus, Insufficient Evidence) and labels (Imperative or Conditional). To see more detail on the evidence from which the following recommendations were drawn, use the hyperlinks in the Supporting Evidence Section below.
-
Recommendation(s)
CF: Frequency of Nutrition Assessment
In individuals with cystic fibrosis (CF), a full nutrition assessment should be conducted by an RDN or international equivalent:
- at diagnosis;
- when indicated by nutrition screening;
- up to monthly for the first 6 months of life; up to every other month until 1 year of age; and up to quarterly until 2 years of age;
- annually for individuals greater than 2 years of age and;
- when disease or treatment course changes.
Rating: Consensus
ImperativeCF: Nutrition Assessment Components
In individuals with cystic fibrosis (CF), the RDN or international equivalent should diagnose nutrition status, including underweight and overweight, based on a comprehensive assessment of weight and growth history and stature, body composition, disease severity, laboratory values, drug-nutrient interactions/implications, and estimated energy expenditure compared to client/parent report of dietary intake and food security status, since CF nutrition pathology is highly individual and maintaining optimal nutrition status is a necessary component of preventing disease progression.
Rating: Strong
Imperative-
Risks/Harms of Implementing This Recommendation
There are no obvious risks or harms associated with these nutrition assessment recommendations. Time spent in cystic fibrosis clinics is the most common objection to nutrition assessment.
-
Conditions of Application
Changes in Disease Course or Treatment: Significant changes in disease or treatment course that warrant full nutrition assessment include, but are not limited to: diagnosis of a co-morbidity (ex: CFRD, liver disease, CF-related bone disease); unintentional weight loss or gain; hospitalization for pulmonary exacerbation; pre-, peri- and post- lung transplantation; exacerbation in gastrointestinal symptoms; beginning or ceasing enteral or parenteral nutrition; beginning, change or cessation of medications including CFTR modulation therapy or PERT; and abnormal nutrition-related laboratory values.
Socioeconomic Status (SES): There is potential that individuals and families with lower SES will have more difficulty paying for additional testing to diagnose nutrition status beyond BMI/weight measurements. In these cases, practitioners may utilize low-cost options such as nutrition-focused-physical exams.
WHO vs CDC growth curves: In accordance with recommendations for the general population, practitioners may use WHO growth standards for infants 0-24 months of age and begin using CDC growth charts at age two (Grummer-Strawn et al 2010) though this is not currently specified in guidance for the CF population (Cystic Fibrosis Foundation, 2019) For infants and children 0-24 months of age, WHO growth charts, compared to CDC growth charts, were less likely to define children as <50th percentile for weight-for-age (WFA) and weight-for-length (WFL) (Machogu et al 2015, Zhang et al 2015) Therefore, if practitioners use WHO growth charts to screen for growth, percentiles <70th percentile may be used to identify nutrition risk rather than the <50th percentile recommended when using CDC growth charts.
-
Potential Costs Associated with Application
There is potential that using certain methods to assess nutrition status will be cost prohibitive or difficult to institute in clinical practice (ex: DEXA for body composition or laboratory measures such as essential fatty acid levels), particularly for individuals with low socio-economic statis and/or without insurance coverage. Nutrition assessment and interventions can reduce inequities by assisting individuals and families in determining options for improving or maintaining nutrition and disease progression as well as accessing resources to minimize food insecurity. In clinical practice, families who attend CF clinic regularly and are connected with resources are more likely to benefit than those who seldom attend CF clinic and are unaware of available resources (Cystic Fibrosis Foundation, 2019).
-
Recommendation Narrative
Background. Malnutrition can occur quickly and insidiously in individuals with cystic fibrosis (CF) due to multiple dynamic factors including malabsorption, decreased appetite, increased energy expenditure, CF related diabetes, and psychosocial factors. Health care providers, individuals with CF and their families should recognize that representation of adequate nutritional status extends beyond the sole use of BMI, and should reflect body composition, laboratory values, energy expenditure, and dietary intake. Consistent, individualized, and ongoing assessment of nutrition status may prevent or remediate the effects of malnutrition on the progression of pulmonary disease and improve quality of life for individuals with CF.
Evidence. There was no evidence that examined overall nutrition assessment protocols in isolation, but in quality improvement studies, increased contacts between individuals with CF/family and an RDN, including nutrition screening and assessment, resulted in improved anthropometric outcomes and decreased antibiotic use in pediatric individuals with CF (Ledger et al 2013, Starket al 2011, Savant et al 2014, Ramirez et al 2015) There were no studies of this nature available that examined adults with CF.
The systematic review supporting this guideline clearly demonstrated that undernutrition, defined by weight and length/height measures, is longitudinally associated with pulmonary decline and mortality in pediatric individuals and adults with CF. (Academy of Nutrition and Dietetics 2019, Darrah et al 2016, Emerson et al 2002, Goss et al 2018, Keller et al 2003, Konstan et al 2007, Lai et al 2009, Machogu et al 2015, McPhail et al 2008, Sanders et al 2014, Sanders et al 2015, Sanders et al 2015, Sanders et al 2018, Usatin et al 2017, Welsh et al 2014, Woestenenk et al 2014, Yen et al 2013, Amadori et al 2009, Ramos et al 2017, George et al 2011, Chamnan et al 2010, Stephensonet al 2015, Vieni et al 2013, McColley et al 2017). However, only evaluating weight and growth measures may overlook other complex factors that contribute to poor nutritional status and ultimately poorer lung function. For example, in adult participants with CF, using a BMI cut-off of ≤18.5 kg/m2 to identify malnutrition led to classifying subjects with higher BMI values as well-nourished despite having inadequate fat free mass (Hollander et al 2014, King et al 2010).
For most nutrition assessment parameters examined (ex: handgrip strength, micronutrient deficiencies, lipid profile and Nutrition Focused Physical Exam), there was little or no evidence available in either the pediatric or adult CF population describing 1) validity and reliability compared to a reference standards (Academy of Nutrition and Dietetics Evidence Analysis Library, 2019) and 2) longitudinal relationship with mortality, FEV1 % predicted or quality of life (Academy of Nutrition and Dietetics, 2019). Therefore, it is unclear exactly how or how often these nutrition parameters should be assessed.
Implementation. When assessing nutrition challenges and needs, RDNs must consider a host of other factors that may vary considerably between individuals with CF and will play an integral role in determining nutrition diagnosis and, consequently, nutrition intervention. For example, a large proportion of individuals with CF acquire CFRD over time, which, if not diagnosed or treated properly, is longitudinally associated with lung function decline and mortality (Goss et al 2018, Welsh et al 2014, Amadori et al 2009, Chamnan et al 2010, Vieni et al 2013, Hofer et al 2012). CFRD screening and management can prevent adverse effects associated with uncontrolled diabetes. Glucose homeostasis and insulin-related laboratory values must be carefully monitored and managed by the RDN with the interdisciplinary CF healthcare team, to prevent diabetes-related complications. In addition, RDNs must be aware of changing trends in CF that may need to be regularly considered during nutrition assessment, such as increasing rates of overweight in the CF population (Cystic Fibrosis Patient Registry 2017) or use of newly developed medications.
The desirable effects of consistent, comprehensive nutrition care are likely to be large. Standardized clinic protocols and procedures are helpful to assure that accurate and timely prerequisite measurements and laboratory tests are available. As life expectancy projections increase (Keogh et al 2018), nutrition assessment is key for adapting to the evolving nutrition challenges that present in an individual with CF throughout a lifetime. The recommendations for nutrition assessment reflect current practice in most accredited CF centers. MNT should be incorporated into overall interdisciplinary clinical care and conducted in partnership with families and individuals with CF.
Components of Comprehensive Nutrition Assessment. For individuals with CF, when conducting nutrition assessment to determine if and what nutrition interventions are necessary, RDNs should evaluate:
Anthropometrics
- Growth parameters: Pediatrics
- Conducted at each clinic visit
- Infants < 2 years: Head circumference percentiles and z scores, weight-for-age weight-for-length, length-for-age percentiles and z scores using WHO growth charts
- Pediatrics (≤18 years): Weight-for-age percentiles and z scores; height-for-age percentiles and z scores; BMI-for-age for children 2 years and older using CDC growth charts and weight status categories (Division of Nutrition 2019)
- When possible, biological parental height should be considered, or adjusted for, when evaluating linear growth (EBMcalc 2019, Tanner et al 1970)
- CF Centers and team members should collaborate to determine strategies for Tanner staging for adolescents, since self-reports can be inaccurate and Tanner exams can seem invasive.
- Weight parameters: Adults
- Adult (> 18 years): Weight, height and BMI using CDC weight status categories (Division of Nutrition 2019)
- Body composition (please see Body Composition Assessment section for details)
- Conducted during each nutrition assessment
- fat mass, fat free mass, andbone mineral density according to external guidelines (please see Recommendation Overview Table)
Biochemical (Please see “Nutrition Assessment of Biochemical Values” section for details)
- Glucose homeostasis measures, such as response to OGTT.
- Continuous glucose monitoring systems are not indicated for diagnosis of CFRD but may be ordered by an endocrinologist and data can be utilized by RDNs to guide nutrition care.
- Fat soluble vitamins status including for levels of Vitamins A, D3 (25-OH-D) and E as well as prothrombin time (PT) for vitamin K)
- Lipid profile, as indicated (National Center for Chronic Disease Prevention and Health Promotion 2019, American Academy of Pediatrics 2016)
- Basic metabolic profile including sodium (Na), chloride (Cl), potassium (K), BUN, glucose, and liver enzyme levels
- Urine sodium, as indicated (Borowitz et al 2002)
Clinical
- Pulmonary function, including FEV1% predicted and pulmonary exacerbations
- Lung transplant and other medical history
- Pancreatic insufficiency and pancreatic enzyme replacement therapy
- Other medications that may alter nutrient intake or needs, such as appetite stimulants, growth hormones, insulin and/or CFTR modulation therapy
- Gastrointestinal symptoms (constipation, symptoms of malabsorption including diarrhea/steatorrhea, DIOS, GERD, small intestinal bacterial overgrowth, C. difficile infection)
- Co-morbidities, including CF-related diabetes, CF- related liver disease, CF-related bone disease, gallbladder/kidney issues, sinus disease or other gastrointestinal comorbidities such as Celiac Disease or inflammatory bowel disease
- Nutrition focused physical exam (Academy of Nutrition and Dietetics, 2016)
Dietary
- Dietary intake history, including meal patterns. Quantitative assessment of dietary intake, including energy intake, may be assessed at least annually
- Nutrient requirements, including energy expenditure using indirect calorimetry or appropriate prediction equations (please see section Assessment of Energy Requirements)
- Eating environment and challenges for the individual with CF and family, including level of food security and access to resources to implement RDN recommendations
- Values/beliefs related to dietary choices (ex: vegetarian, vegan, religious observations)
Other
- Beliefs about the impact of nutrition status on CF disease progression
- Nutrition goals for the person with CF and family, such as weight status goals, dietary intake goals, reduction of nutrition-related symptoms or improved body image
- Social determinants of health
- Values and beliefs about food and nutrition
Medical nutrition therapy follows the Nutrition Care Process (NCP) model, which directs how a client moves through nutrition assessment to nutrition intervention (Swan et al 2017). In the NCP, the RDNs will organize data collected by nutrition assessment and reassessment for comparison with defining characteristics of suspected diagnoses. RDNs should look for patterns and relationships among collected data to determine diagnoses, identify etiology that may be impacted by intervention, and identifying signs or symptoms that can be measured to determine progress during reassessment (Swan et al 2017) Following comprehensive nutrition assessment, the RDN should work with the individual, family and interdisciplinary health care team to determine health care priorities, including nutrition priorities. Nutrition goals and management should be integrated into overall plan of care. When determining primary nutrition goals following diagnosis, RDNs should consider not only disease pathology and biological characteristics, but also current dietary intake, cultural factors, psychosocial needs, the patient’s/family’s goals and preferences, lifestyle and mental and emotional health. RDNs are poised to translate assessment findings into individualized education and counseling, in order to co-produce a nutrition care plan that works for the individual with CF. As more information is gathered, nutrition diagnoses may evolve, dictating a modification to the treatment plan.
- Growth parameters: Pediatrics
-
Recommendation Strength Rationale
Evidence describing the effect of MNT protocols on outcomes was based on Grade III evidence. Evidence describing the relationships between nutrition parameters and hard outcomes was Grades I-III. However, the “effect” of nutrition assessment is difficult to gauge in studies, since it is the first step in Nutrition Care Process and subsequent steps also affect nutrition-related outcomes. Therefore, the evidence was also supported by clinical expertise. Suggested frequency of nutrition assessment contacts is based on general nutrition practice as well as clinical experience, guidance from the CF Foundation (Stallings et al 2008) and quality improvement or comparative studies (Ledger et al 2013, Stark et al 2011, Savant et al 2014, Ramirez et al 2015).
-
Minority Opinions
Consensus reached.
-
Supporting Evidence
The recommendations were created from the evidence analysis on the following questions. To see detail of the evidence analysis, click the blue hyperlinks below (recommendations rated consensus will not have supporting evidence linked).
In participants with CF, how does medical nutrition therapy (MNT or nutrition counseling) provided by a registered dietitian or international equivalent affect lung function?
In participants with CF, how does medical nutrition therapy (MNT or nutrition counseling) provided by a registered dietitian or international equivalent affect quality of life?
In participants with CF, how does medical nutrition therapy (MNT or nutrition counseling) provided by a registered dietitian or international equivalent affect anthropometric measures and growth?
In participants with CF, how does medical nutrition therapy (MNT or nutrition counseling) provided by a registered dietitian or international equivalent affect morbidities (length of stay, antibiotic use)?
In pediatric participants with CF, what is the longitudinal relationship (at least 3 months) between weight and growth parameters and FEV1?
In pediatric participants with CF, what is the longitudinal relationship (at least 3 months) between weight and growth parameters and mortality?
In pediatric and adult participants with CF combined, what is the longitudinal relationship (at least 3 months) between weight parameters and mortality?
In adults with CF, what is the longitudinal relationship (at least 3 months) between weight parameters and FEV1?
In adults with CF, what is the longitudinal relationship (at least 3 months) between weight parameters and mortality?
In adults with CF, which weight parameters are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In pediatric participants with CF, what is the longitudinal relationship (at least 3 months) between cystic fibrosis-related diabetes (CFRD) and FEV1?
In pediatric participants with CF, what is the longitudinal relationship (at least 3 months) between cystic fibrosis-related diabetes (CFRD) and Quality of Life or Mortality?
In adults with CF, what is the longitudinal relationship (at least 3 months) between cystic fibrosis-related diabetes (CFRD) and FEV1 or mortality?
In adults with CF, what is the longitudinal relationship (at least 3 months) between cystic fibrosis-related diabetes (CFRD) and QoL?
In pediatric and adults with CF combined, what is the longitudinal relationship (at least 3 months) between CFRD and mortality?
In pediatric participants with CF, what is the longitudinal relationship (at least 3 months) between vitamin D levels and FEV1?
In participants with CF, what is the longitudinal relationship (at least 3 months) between composite nutrition assessment/screening scores and hard outcomes (FEV1, Quality of Life or mortality)?
In participants with CF, what is the longitudinal relationship (at least 3 months) between Nutrition Focused Physical Exam and hard outcomes (FEV1, Quality of Life or mortality)?
In participants with CF, what is the longitudinal relationship (at least 3 months) between body composition and hard outcomes (FEV1, Quality of Life or mortality)?
In participants with CF, what is the longitudinal relationship (at least 3 months) between handgrip strength and hard outcomes (FEV1, Quality of Life or mortality)?
In participants with CF, what is the longitudinal relationship (at least 3 months) between essential fatty acid (EFA) deficiencies and FEV1?
In participants with CF, what is the longitudinal relationship (at least 3 months) between micronutrient deficiencies (vitamins A, D, E and zinc) and hard outcomes (FEV1, Quality of Life or mortality)?
In participants with CF, what is the longitudinal relationship (at least 3 months) between essential fatty acid (EFA) deficiencies and QoL or mortality?
In participants with CF, what is the longitudinal relationship (at least 3 months) between lipid profile and FEV1?
In participants with CF, what is the longitudinal relationship (at least 3 months) between lipid profile and QoL or mortality?
In pediatric participants with CF, which composite nutrition scores (assessment and screening tools) are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In pediatric participants with CF, 2 years of age and younger, which weight and growth parameters are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In pediatric participants with CF 2-20 years of age, which weight and growth parameters are valid and reliable compared to reference standards, as measured by validity and reliability studies?
In pediatric participants with CF, which body composition parameters are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In pediatric participants with CF, what is the validity and/or reliability of Nutrition Focused Physical Exam and Handgrip Strength valid compared to reference standards?
In adults with CF, which weight parameters are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In adults with CF, which body composition parameters are valid and reliable compared to reference standards, as measured by validity and/or reliability studies?
In adults with CF, what is the validity and/or reliability of Composite Nutrition Scores, Nutrition Focused Physical Exam and Handgrip Strength compared to reference standards?-
References
Darrah R, Nelson R, Damato E, Decker M, Matthews A, Hodges C. Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biological Research for Nursing 2016; 18:498-504
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology 2002; 34:91-100
Goss C, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, Fink A, Elbert A, Quon B, Stephenson A. Comparison of nutrition and lung function outcomes in [atients with cystic fibrosis living in Canada and the United States. American Journal of Respiratory and Critical Care Medicine 2018; 197:768-775
Keller B, Aebischer C, Kraemer R, Schöni M. Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation. Journal of Cystic Fibrosis 2003; 2:76-83
Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S, Stokes D, Wohl M, Wagener J, Regelmann W, Johnson C. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. Journal of Pediatrics 2007; 151:134-9
Lai H, Shoff S, Farrell P. Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis. Pediatrics 2009; 123:714-22
McPhail G, Acton J, Fenchel M, Amin R, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. The Journal of Pediatrics 2008; 153:752-7
Sanders D, Li Z, Laxova A, Rock M, Levy H, Collins J, Ferec C, Farrell P. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Annals of the American Thoracic Society 2014; 11:63-72
Sanders D, Emerson J, Ren C, Schechter M, Gibson R, Morgan W, Rosenfeld M. Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis. Annals of the American Thoracic Society 2015; 12:1170-6
Sanders D, Fink A, Mayer-Hamblett N, Schechter M, Sawicki G, Rosenfeld M, Flume P, Morgan W. Early life growth trajectories in cystic fibrosis are associated with pulmonary function at age 6 years. Journal of Pediatrics 2015; 167:1081-8.e1
Sanders D, Zhang Z ,Farrell P, Lai H. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. Journal of Cystic Fibrosis 2018; 17:528-535
Usatin D, Yen E, McDonald C, Asfour F, Pohl J, Robson J. Differences between WHO AND CDC early growth measurements in the assessment of cystic fibrosis clinical outcomes. Journal of Cystic Fibrosis 2017; 16:503-509
Welsh L, Robertson C, Ranganathan S. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatric Pulmonology 2014; 49:873-7
Woestenenk J, Stellato R, Terheggen-Lagro S, van der Ent C, Houwen R. The relationship between body growth and pulmonary function in children with cystic fibrosis. Acta Paediatrica 2014; 103:162-7
Yen E, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. The Journal of Pediatrics 2013; 162:530-535.e1
McColley S, Schechter M, Morgan W, Pasta D, Craib M, Konstan M. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology 2017; 52:909-915
Chamnan P, Shine B, Haworth C, Bilton D, Adler A. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33:311-6
Stephenson A, Tom M, Berthiaume Y, Singer L, Aaron S, Whitmore G, Stanojevic S. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. The European Respiratory Journal 2015; 45:670-9
Vieni G, Faraci S, Collura M, Lombardo M, Traverso G, Cristadoro S, Termini L, Lucanto M, Furnari M, Trimarchi G, Triglia M, Costa S, Pellegrino S, Magazzù G. Stunting is an independent predictor of mortality in patients with cystic fibrosis. Clinical Nutrition (Edinburgh, Scotland) 2013; 32:382-5
McCauley L, Thomas W, Laguna T, Regelmann W, Moran A, Polgreen L. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. Annals of the American Thoracic Society 2014; 11:198-204
Welsh L, Robertson C, Ranganathan S. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatric Pulmonology 2014; 49:873-7
Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respiratory Medicine 2009; 103:407-13
George P, Banya W, Pareek N, Bilton D, Cullinan P, Hodson M, Simmonds N. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ (Clinical research ed.) 2011; 342:d1008
Ramos K, Quon B, Heltshe S, Mayer-Hamblett N, Lease E, Aitken M, Weiss N, Goss C. Heterogeneity in survival in adult patients with cystic fibrosis with FEV < 30% of predicted in the United States. Chest 2017; 151:1320-1328
Maqbool A, Schall J, Garcia-Espana J, Zemel B, Strandvik B, Stallings V. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2008; 47:635-44
Ollero M, Astarita G, Guerrera I, Sermet-Gaudelus I, Trudel S, Piomelli D, Edelman A. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. Journal of Lipid Research 2011; 52:1011-22
Chamnan P, Shine B, Haworth C, Bilton D, Adler A. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33:311-6
Hofer M, Schmid C, Benden C, Speich R, Inci I, Weder W, Boehler A. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. Journal of Cystic Fibrosis 2012; 11:131-6
McDonald C. Validation of a nutrition risk screening tool for children and adolescents with cystic fibrosis ages 2-20 years. Journal of Pediatric Gastroenterology and Nutrition 2008; 46:438-46
Souza Dos Santos Simon M, Forte G, da Silva Pereira J, da Fonseca Andrade Procianoy E, Drehmer M. Validation of a Nutrition Screening Tool for Pediatric Patients with Cystic Fibrosis. Journal of the Academy of Nutrition and Dietetics 2016; 116:813-8
Heltshe S, Borowitz D, Leung D, Ramsey B, Mayer-Hamblett N. Early attained weight and length predict growth faltering better than velocity measures in infants with CF. Journal of Cystic Fibrosis 2014; 13:723-9
Machogu E, Cao Y, Miller T, Simpson P, Levy H, Quintero D, Goday P. Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2015; 60:378-83
Zhang Z, Shoff S, Lai H. Comparing the Use of Centers for Disease Control and Prevention and World Health Organization Growth Charts in Children with Cystic Fibrosis through 2 Years of Age. The Journal of Pediatrics 2015; 167:1089-95
Woestenenk J,Gulmans V,van der Ent C,Houwen R. Height Assessment in the Dutch-Origin Pediatric Cystic Fibrosis Population. Nutrition in Clinical Practice 2017; 32:130-132
Charatsi A, Dusser P, Freund R, Maruani G, Rossin H, Boulier A, Le Bourgeois M, Chedevergne F, de Blic J, Letourneur A, Casimir G, Jais J, Sermet-Gaudelus I. Bioelectrical impedance in young patients with cystic fibrosis: Validation of a specific equation and clinical relevance. Journal of Cystic Fibrosis 2016; 15:825-833
Murphy A, Buntain H, Wong J, Greer R, Wainwright C, Davies P. The use of air displacement plethysmography in children and adolescents with cystic fibrosis. European Journal of Clinical Nutrition 2004; 58:985-9
Puiman P, Francis P, Buntain H, Wainwright C, Masters B, Davies P. Total body water in children with cystic fibrosis using bioelectrical impedance. Journal of Cystic Fibrosis 2004; 3:243-7
Wells G, Heale L, Schneiderman J, Wilkes D, Atenafu E, Coates A, Ratjen F. Assessment of body composition in pediatric patients with cystic fibrosis. Pediatric Pulmonology 2008; 43:1025-32
Williams J, Wells J, Wilson C, Haroun D, Lucas A, Fewtrell M. Evaluation of Lunar Prodigy dual-energy X-ray absorptiometry for assessing body composition in healthy persons and patients by comparison with the criterion 4-component model. The American Journal of Clinical Nutrition 2006; 83:1047-54
Williams J, Wells J, Benden C, Jaffe A, Suri R, Wilson C, Fewtrell M. Body composition assessed by the 4-component model and association with lung function in 6-12-y-old children with cystic fibrosis. American Journal of Clinical Nutrition 2010; 92:1332-43
Hollander F, van Pierre D, de Roos N, van de Graaf E, Iestra J. Effects of nutritional status and dietetic interventions on survival in Cystic Fibrosis patients before and after lung transplantation. Journal of Cystic Fibrosis 2014; 13:212-8
Hollander F, De Roos N, De Vries J, Van Berkhout F. Assessment of nutritional status in adult patients with cystic fibrosis: whole-body bioimpedance vs body mass index, skinfolds, and leg-to-leg bioimpedance. Journal of the American Dietetic Association 2005; 105:549-55
King S, Nyulasi I, Strauss B, Kotsimbos T, Bailey M, Wilson J. Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index. Nutrition (Burbank, Los Angeles County, Calif.) 2009; 26:753-9
King S, Wilson J, Kotsimbos T, Bailey M, Nyulasi I. Body composition assessment in adults with cystic fibrosis: comparison of dual-energy X-ray absorptiometry with skinfolds and bioelectrical impedance analysis. Nutrition (Burbank, Los Angeles County, Calif.) 2005; 21:1087-94
Ledger S, Owen E, Prasad S, Goldman A, Willams J ,Aurora P. A pilot outreach physiotherapy and dietetic quality improvement initiative reduces IV antibiotic requirements in children with moderate-severe cystic fibrosis. Journal of Cystic Fibrosis 2013; 12:766-72
Ramírez I, Filbrun A, Hasan A, Kidwell K, Nasr S. Improving nutritional status in a pediatric cystic fibrosis center. Pediatric Pulmonology. 2015; 50:544-551
Stark L, Opipari-Arrigan L, Quittner A, Bean J, Powers S. The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF. Pediatric Pulmonology. 2011; 46:31-35.
Savant A, Britton L, Petren K, McColley S, Gutierrez H. Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives. BMJ Quality & Safety. 2014; 23:i81-i89 -
References not graded in Academy of Nutrition and Dietetics Evidence Analysis Process
- Academy of Nutrition and Dietetics Evidence Analaysis Library. "In individuals with CF, what is the longitudinal relationship (at least 3 months) between weight and growth parameters and FEV1?". Academy of Nutrition and Dietetics. Cystic Fibrosis Systematic Review web site. https://www.andeal.org/topic.cfm?menu=5876&cat=5979. Updated August 2019. Accessed September 10, 2019.
- Academy of Nutrition and Dietetics Evidence Analysis Library. In individuals with CF, what is the relationship between nutrition parameters and hard outcomes? Academy of Nutrition and Dietetics. Cystic Fibrosis web site. https://www.andeal.org/topic.cfm?menu=5876&cat=5979. Published 2019. Accessed September 25, 2019.
- Academy of Nutrition and Dietetics Evidence Analysis Library. In individuals with CF, what is the validity and reliability or nutrition assessment methods compared to reference standards, as measured by validity and/or reliability studies? Evidence Analysis Library Cystid Fibrosis Systematic Review web site. https://www.andeal.org/topic.cfm?menu=5876&cat=5942. Published 2019. Accessed September 26, 2019.
- Academy of Nutrition and Dietetics. Pediatric Nutrition Focused Physical Exam Pocket Guide. Chicago, IL: Academy of Nutrition and Dietetics; 2016.
- American Academy of Pediatrics. 2016 Recommendations for Preventive Pediatric Health Care. Pediatrics. 2016;137.
- Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35(3):246-59.Cystic Fibrosis Foundation. Nutritional Basics. Cystic Fibrosis Foundation. https://www.cff.org/Life-With-CF/Daily-Life/Fitness-and-Nutrition/Nutrition/Getting-Your-Nutrients/Nutritional-Basics/. Accessed September 25, 2019.
- Cystic Fibrosis Foundation Patient Registry. 2017 Annual Data Report. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf. Accessed October 15, 2019.
- Cystic Fibrosis Foundation. Care Centers. Cystic Fibrosis Foundation. https://www.cff.org/Care/Care-Centers/. Published 2019. Accessed October 15, 2019.
- Grummer-Strawn LM, Reinold C, Krebs NF. Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States. MMWR Recomm Rep. 2010;59(Rr-9):1-15.Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17(2):218-227.
- EBMcalc. EBMcalc An Educational Medical Reference. https://ebmcalc.com/HeightPotential.htm. Published 2019. Accessed January 9, 2020.
- National Center for Chronic Disease Prevention and Health Promotion Getting Your Cholesterol Checked. U.S. Department of Health and Human Services. https://www.cdc.gov/cholesterol/cholesterol_screening.htm. Published 2019. Accessed September 2019.
- Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108(5):832-839.
- Swan WI, Vivanti A, Hakel-Smith NA, et al. Nutrition Care Process and Model Update: Toward Realizing People-Centered Care and Outcomes Management. J Acad Nutr Diet. 2017;117(12):2003-2014.
- Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child. 1970;45(244):755-762.
-
References